XBiotech Inc

XBiotech operates with a strong liquidity position, as evidenced by its cash and equivalents of $125.55 million, which significantly exceeds its total liabilities of $9.73 million, resulting in a current ratio of 16.01. The company's price-to-book ratio of 0.54 and price-to-tangible-book ratio of 0.54 suggest that the market values the company at a discount to its book value, potentially indicating undervaluation or concerns about future earnings. Profitability metrics show a challenging financial landscape for XBiotech. The company reported a net loss of $45.54 million and an operating loss of $55.69 million, resulting in a negative return on equity of -32.45% and a negative return on assets of -30.34%. These figures are below the industry median for profitability, indicating that the company is underperforming relative to its peers in terms of generating returns on invested capital and assets. Geographically, XBiotech's revenue is not disclosed by segment or region in the available data, making it difficult to assess geographic exposure or revenue concentration. However, the company's operations are primarily in the biotechnology sector, which is subject to regulatory and market risks that can affect revenue stability. The company's growth trajectory is constrained by its current financial performance. With a net loss and negative operating cash flow of $39.92 million, XBiotech is not generating positive cash flows from operations, which is a critical factor for sustainable growth. The absence of long-term debt and the presence of significant cash reserves suggest that the company has the financial flexibility to fund operations and research and development activities without immediate dilution or liquidity pressures. Risk factors for XBiotech include its reliance on successful clinical trials and regulatory approvals for its drug candidates, as well as the high costs and uncertainties associated with biotechnology research and development. The company's low ESG governance score of 29.86 and high ESG controversies score of 100.00 indicate potential governance and reputational risks that could impact investor confidence and operational stability. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. Recent events and filings do not show any significant changes in the company's financial or operational status. The last actual EPS was -$0.36, and the last actual revenue was $43.997 million, reflecting ongoing financial challenges. The company's capital expenditures were minimal at -$289,000, suggesting a conservative approach to capital spending.